Literature DB >> 28163053

Myocyte enhancer factor 2C and its directly-interacting proteins: A review.

Chen Dong1, Xue-Zhou Yang1, Chen-Yan Zhang2, Yang-Yang Liu1, Ren-Bin Zhou1, Qing-Di Cheng1, Er-Kai Yan1, Da-Chuan Yin3.   

Abstract

Myocyte enhancer factor 2C (MEF2C) is a transcription factor of MADS box family involved in the early development of several human cells including muscle (i.e., skeletal, cardiac, and smooth), neural, chondroid, immune, and endothelial cells. Dysfunction of MEF2C leads to embryo hypoplasia, disorganized myofibers and perinatal lethality. The main role of MEF2C is its regulation of muscle development. It has been reported that MEF2C-knockout mice die on embryonic day 9.5 from unnatural development of cardiovascular. The effects of MEF2C are mediated by its directly-interacting proteins; therefore, the investigation of these interactions is critical in order to clarify MEF2C's biological function. In this study, we review twenty-five proteins that directly interact with MEF2C, including nineteen proteins related to muscle development, four proteins related to neural cell development, one protein related to chondroid cell development, four proteins related to immune cell development, and two proteins related to endothelial cell development. Among these proteins, the interaction of MEF2C with MRFs is important for differentiation of developing muscle cells. MEF2C interacts with Sox18 for endothelial vessel morphogenesis. The interaction of MEF2C with Cabin1 is important for maintaining T-cell inactivation. Investigating the interactions of MEF2C and its directly-interacting proteins is not only helpful to understand of the physiological function of MEF2C, but also provides a target for future rational drug design.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Directly-interacting protein; Function of MEF2C; MEF2C-related diseases; Myocyte enhancer factor 2C; Structure of MEF2C

Mesh:

Substances:

Year:  2017        PMID: 28163053     DOI: 10.1016/j.pbiomolbio.2017.02.002

Source DB:  PubMed          Journal:  Prog Biophys Mol Biol        ISSN: 0079-6107            Impact factor:   3.667


  16 in total

1.  A Novel MEF2C Loss-of-Function Mutation Associated with Congenital Double Outlet Right Ventricle.

Authors:  Cai-Xia Lu; Wei Wang; Qian Wang; Xing-Yuan Liu; Yi-Qing Yang
Journal:  Pediatr Cardiol       Date:  2018-02-21       Impact factor: 1.655

2.  Cardiovascular development and survival require Mef2c function in the myocardial but not the endothelial lineage.

Authors:  Stefan C Materna; Tanvi Sinha; Ralston M Barnes; Kelly Lammerts van Bueren; Brian L Black
Journal:  Dev Biol       Date:  2018-12-03       Impact factor: 3.582

3.  MEF2C silencing downregulates NF2 and E-cadherin and enhances Erastin-induced ferroptosis in meningioma.

Authors:  Zhongyuan Bao; Lingyang Hua; Yangfan Ye; Daijun Wang; Chong Li; Qing Xie; Hiroaki Wakimoto; Ye Gong; Jing Ji
Journal:  Neuro Oncol       Date:  2021-12-01       Impact factor: 12.300

4.  Genotypes and Phenotypes of MEF2C Haploinsufficiency Syndrome: New Cases and Novel Point Mutations.

Authors:  Lin Wan; Xinting Liu; Linyan Hu; Huimin Chen; Yulin Sun; Zhichao Li; Zhenfang Wang; Zhi Lin; Liping Zou; Guang Yang
Journal:  Front Pediatr       Date:  2021-05-13       Impact factor: 3.418

Review 5.  The role of histone deacetylase 4 during chondrocyte hypertrophy and endochondral bone development.

Authors:  Zhi Chen; Zhiwei Zhang; Li Guo; Xiaochun Wei; Yang Zhang; Xiaojian Wang; Lei Wei
Journal:  Bone Joint Res       Date:  2020-05-16       Impact factor: 5.853

6.  Covalent CDK7 Inhibitor THZ1 Inhibits Myogenic Differentiation.

Authors:  Xinqi Ma; Xielan Kuang; Qing Xia; Zixin Huang; Yuting Fan; Jie Ning; Jiajie Wen; Han Zhang; Jianhua Yan; Qingjiong Zhang; Huangxuan Shen; Chongde Long
Journal:  J Cancer       Date:  2018-08-06       Impact factor: 4.207

7.  Downregulation of circulating miR 802-5p and miR 194-5p and upregulation of brain MEF2C along breast cancer brain metastasization.

Authors:  Marta Sereno; János Haskó; Kinga Molnár; Sarah J Medina; Zita Reisz; Rui Malhó; Mafalda Videira; László Tiszlavicz; Stephanie A Booth; Imola Wilhelm; István A Krizbai; Maria Alexandra Brito
Journal:  Mol Oncol       Date:  2020-02-05       Impact factor: 6.603

8.  MEF2C loss-of-function mutation contributes to congenital heart defects.

Authors:  Xiao-Hui Qiao; Fei Wang; Xian-Ling Zhang; Ri-Tai Huang; Song Xue; Juan Wang; Xing-Biao Qiu; Xing-Yuan Liu; Yi-Qing Yang
Journal:  Int J Med Sci       Date:  2017-09-08       Impact factor: 3.738

9.  Novel MEF2C point mutations in Chinese patients with Rett (-like) syndrome or non-syndromic intellectual disability: insights into genotype-phenotype correlation.

Authors:  Jiaping Wang; Qingping Zhang; Yan Chen; Shujie Yu; Xiru Wu; Xinhua Bao; Yongxin Wen
Journal:  BMC Med Genet       Date:  2018-10-30       Impact factor: 2.103

Review 10.  MicroRNA regulatory networks in the pathogenesis of sarcopenia.

Authors:  Jiayu Yin; Zhiyuan Qian; Yuqi Chen; Yi Li; Xiang Zhou
Journal:  J Cell Mol Med       Date:  2020-04-12       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.